Peptide Receptor Radionuclide Therapy (PRRT) Market: Incur Rapid Extension During 2018 – 2026 With Top Players Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal Trials Group, Toulouse University Hospital

Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy a peptide similar to the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce radionuclide which is then injected into the patient’s body. This combination binds to the neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of radiation directly to the tumor cells.

Get The PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2731

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Drivers

Increasing number of drug approvals by regulatory bodies is expected to drive the global peptide receptor radionuclide therapy market growth over the forecast period. For instance, in January 2018, Advanced Accelerator Applications S.A. received an approval from U.S. Food & Drug Administration for Lutathera, a peptide receptor radionuclide therapy. It is used for treating gastroenteropancreatic neuroendocrine tumors. Its phase 3 study showed 79% reduction in the disease progression. Moreover, it is the only approved peptide receptor radionuclide therapy drug.

Furthermore, key players are also focused on research and development activities related to peptide receptor radionuclide therapy which is expected to accelerate the global peptide receptor radionuclide therapy market growth. For instance, in July 2017, National Institute of Health commenced its clinical trial study on Y-DOTATOC. The drug is currently in the early phase of trials, and is being evaluated for micro-dosing. It will be used for treating neuroendocrine tumors. Such development of drugs is expected to boost the global peptide receptor radionuclide therapy market growth.

Also, strategies such as mergers, acquisitions, partnerships, and collaborations by key players related to peptide receptor radionuclide therapy are expected to propel the global peptide receptor radionuclide therapy market growth over the forecast period.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Key Players

Some of the major player operating in the global peptide receptor radionuclide therapy (PRRT) market include, Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal Trials Group, Toulouse University Hospital, Peking University, and others.

Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2731

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Regional Analysis

North America is expected to be a dominant region in the peptide receptor radionuclide therapy market. Higher incidences of prostate cancer is expected to support the global peptide receptor radionuclide therapy market growth. According to Center of Disease Control and Prevention’s data for 2016, around 192,443 people suffered from prostate cancer and almost 30,370 died due to it. Prostate cancer is considered the fourth leading cause of death due to cancer. Hence, increasing prevalence of prostate cancer is expected to augment the peptide receptor radionuclide therapy market growth during the forecast period.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.